Akero Therapeutics (AKRO) Competitors

Akero Therapeutics (NASDAQ:AKRO) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.

Do analysts prefer AKRO or GMAB?

Akero Therapeutics currently has a consensus target price of $75.86, indicating a potential upside of 40.27%. Genmab A/S has a consensus target price of $45.20, indicating a potential upside of 129.79%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Akero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the media prefer AKRO or GMAB?

In the previous week, Akero Therapeutics had 46 more articles in the media than Genmab A/S. MarketBeat recorded 59 mentions for Akero Therapeutics and 13 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.56 beat Akero Therapeutics' score of 0.51 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akero Therapeutics	15 Very Positive mention(s)	6 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Does the MarketBeat Community favor AKRO or GMAB?

Genmab A/S received 47 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 64.97% of users gave Akero Therapeutics an outperform vote while only 62.79% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Akero Therapeutics	Outperform Votes 115 64.97%	Underperform Votes 62 35.03%
Genmab A/S	Outperform Votes 162 62.79%	Underperform Votes 96 37.21%

Which has more volatility and risk, AKRO or GMAB?

Akero Therapeutics has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Do institutionals and insiders believe in AKRO or GMAB?

7.1% of Genmab A/S shares are held by institutional investors. 7.9% of Akero Therapeutics shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has better earnings and valuation, AKRO or GMAB?

Genmab A/S has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akero Therapeutics	N/A	N/A	-$151.76M	-$3.75	-14.42
Genmab A/S	$2.39B	5.44	$631.91M	$1.03	19.10

Is AKRO or GMAB more profitable?

Genmab A/S has a net margin of 23.49% compared to Akero Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 14.64% beat Akero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akero Therapeutics	N/A	-32.46%	-29.83%
Genmab A/S	23.49%	14.64%	12.37%

Summary

Genmab A/S beats Akero Therapeutics on 11 of the 16 factors compared between the two stocks.